Michael G. Palfreyman, BPharm, Ph.D., DSc., MRPharmS

Michael G. Palfreyman, BPharm, Ph.D., DSc., MRPharmS

Michael G. Palfreyman, BPharm, Ph.D., DSc., MRPharmS
Past Companies: Marrion Merrell Dow, Amakem, Oculogics, and other companies.
Michael G. Palfreyman is a seasoned leader in the biotechnology and pharmaceutical industries with over 40 years’ experience in leadership positions.

Dr. Palfreyman is President, Palfreyman BioPharm Advisors, Inc.; Chairman of the Board, Amakem, NV (www.amakem.com) and Director, Oculogics, Inc (www.oculogics.com).  In addition, he is Head, R&D Diligence at Torrey Pines Investment (www.torreypinesinv.com)  and Senior R&D Diligence at ChemRar (www.chemrar.ru);  Head, Translational R&D at ChemDiv, Inc.(www.chemdiv.com)  as well as Senior Scientific Advisor for EnVivo Pharmaceuticals, Inc. (www.envivopharma.com), and Scientific Advisor to Avineuro,Inc. (www.avineuro.com), Aminex Therapeutics, (www.aminextherapeutics.com),  and NeuroNascent, Inc. (www.neuronascent.com).

Previously, Michael was VP, Program Management & Product Development at EnVivo Pharmaceuticals where he was responsible for the late stage discovery and preclinical development of two CNS drugs now demonstrating efficacy in Phase 2 clinical testing. As a co-founder NOVACE Corporation, Michael worked closely with Investors and Biotechnology Companies to bring products from discovery through to the value point of clinical validation.

Before joining NOVACE, Michael held a number of executive positions at Psychiatric Genomics, Scriptgen (Anadys) Pharmaceuticals as well as Marion Merrell Dow Research Institute (Sanofi-Aventis). In addition to overseeing research programs in Psychiatric, Neurological, Cardiovascular, Cancer, Infectious, Metabolic and Respiratory Disorders, Dr. Palfreyman’s own research included discovery and development of a number of psychotherapeutic compounds for treatment of psychosis, depression, stroke, epilepsy, emesis, Parkinson’s, Alzheimer’s and Huntington’s diseases. Many of these compounds have entered clinical development and a number have reached the marketplace. He has been an invited speaker and chairperson for a number of international and national conferences, is co-inventor on 35 issued US patents, 3 pending patents and co-author of over 150 scientific articles and book chapters.

Linkedin :